Ophidion, Inc. closes Series Seed round for a total of $1.7M led by Robin Hood Ventures: Philadelphia-based angel investor group Robin Hood Ventures (RHV) announced an initial investment in Ophidion Inc., a Pennsylvania-based private biotechnology company. Ophidion Inc has a platform technology that acts as a Trojan horse to shuttle various cargoes across the blood-brain barrier following intravenous administration. The company is currently focused on developing a pipeline to deliver gene silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease). This seed series will be used to advance the Huntington’s program through preclinical proof of concept, which would de-risk the entire platform as well as position the Huntington’s program to start the IND-enabling studies. In addition to Robin Hood Ventures, four other groups invested in Ophidion Inc. during this seed round. Those groups were: Ben Franklin Technology Partners, Delaware Crossing Investor Group, Viva Incubator Investment Management Limited, and Gaingels.